CINECA IRIS Institutional Research Information System

MASSAIA, Massimo Giovanni Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.097
EU - Europa 7.354
AS - Asia 3.639
AF - Africa 162
SA - Sud America 66
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 29
Totale 20.397
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.926
CN - Cina 2.192
DE - Germania 1.093
IT - Italia 1.066
SE - Svezia 1.004
IE - Irlanda 877
UA - Ucraina 771
FR - Francia 642
SG - Singapore 491
FI - Finlandia 468
AT - Austria 434
KR - Corea 368
GB - Regno Unito 308
PL - Polonia 228
IN - India 170
VN - Vietnam 159
CA - Canada 143
SN - Senegal 112
GR - Grecia 64
JP - Giappone 63
NL - Olanda 63
RU - Federazione Russa 59
DK - Danimarca 58
AU - Australia 46
BE - Belgio 41
HK - Hong Kong 36
BR - Brasile 32
ES - Italia 30
TR - Turchia 29
EU - Europa 26
BY - Bielorussia 25
CH - Svizzera 23
MX - Messico 22
UZ - Uzbekistan 22
TW - Taiwan 21
PT - Portogallo 20
ZA - Sudafrica 16
CL - Cile 13
IR - Iran 13
NO - Norvegia 13
TH - Thailandia 13
HU - Ungheria 12
MU - Mauritius 12
RO - Romania 12
SA - Arabia Saudita 12
CZ - Repubblica Ceca 10
ID - Indonesia 10
CO - Colombia 9
RS - Serbia 9
IL - Israele 8
MK - Macedonia 8
EG - Egitto 7
LU - Lussemburgo 6
MA - Marocco 6
PK - Pakistan 6
AR - Argentina 5
PE - Perù 5
DZ - Algeria 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
HR - Croazia 3
KZ - Kazakistan 3
PH - Filippine 3
AP - ???statistics.table.value.countryCode.AP??? 2
CU - Cuba 2
HN - Honduras 2
IQ - Iraq 2
LV - Lettonia 2
NG - Nigeria 2
SI - Slovenia 2
A1 - Anonimo 1
BD - Bangladesh 1
BG - Bulgaria 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
GI - Gibilterra 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 20.397
Salva come PNG Salva come JPEG
Città #
Beijing 1.702
Chandler 1.226
Dublin 874
Jacksonville 521
Ashburn 490
Houston 447
Vienna 431
Ann Arbor 410
Villeurbanne 355
Medford 322
Nyköping 318
Singapore 299
Fairfield 298
Dearborn 290
Princeton 281
Wilmington 264
Torino 226
Warsaw 215
Woodbridge 191
San Mateo 182
Seattle 138
Redwood City 125
Milan 120
Fremont 117
Cambridge 106
Pisa 96
Turin 96
Dong Ket 93
Boston 82
Boardman 80
Toronto 69
New York 66
Washington 66
Munich 64
Shanghai 58
Santa Clara 52
Düsseldorf 44
Nanjing 43
Pune 43
Rome 43
Hefei 42
Norwalk 40
Falls Church 36
Verona 36
Nürnberg 35
Mountain View 32
Guangzhou 30
Phoenix 29
Brussels 28
Hangzhou 28
Los Angeles 27
Tokyo 27
Lachine 26
Paris 26
Kunming 25
Chengdu 24
San Diego 24
Raritan 20
Lappeenranta 18
Jinan 17
Philadelphia 16
Hebei 15
Helsinki 15
Taipei 15
Chennai 14
Duncan 14
Nanchang 14
Dallas 13
Florence 13
Changsha 12
Des Moines 12
Ottawa 12
Rotterdam 12
Wuhan 12
London 11
San Jose 11
Shenyang 11
Bologna 10
Central District 10
Fuzhou 10
Hyderabad 10
Marseille 10
Padova 10
Piemonte 10
Seoul 10
Amsterdam 9
Den Haag 9
Leawood 9
Mexico 9
Mumbai 9
Palermo 9
Zhengzhou 9
Bogotá 8
Chicago 8
Lisbon 8
Mcallen 8
Provo 8
Silver Spring 8
Upper Marlboro 8
Bengaluru 7
Totale 11.941
Salva come PNG Salva come JPEG
Nome #
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients 446
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 415
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 336
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 304
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 279
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 271
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 254
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 243
Chicago 2014 - 30 years of γδ T cells 242
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 192
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 190
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile 178
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 173
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 171
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 168
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 156
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 154
null 148
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 135
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 133
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 133
Amplification of T cell activation induced by CD73 (ecto-5' nucleotidase) engagement. 131
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 129
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 126
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 125
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 120
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 117
Effective anti-tumor immunomodulatory properties of zoledronic acid 116
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 115
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 115
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 114
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 113
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 111
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 111
CD157 reduces acutemyeloid leukemia cell sensitivity tocytarabine through upregulation of MCL-1 anti-apoptotic protein 111
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. 110
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 110
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 109
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 108
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 105
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
Refractory cytopenia with multilinear dysplasia (RCMD) in patient with Fanconi anaemia 103
Is there a role for allografting in myeloma ?: an update of a comparative study 103
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 103
The tryptophan metabolism in the immune dysregulation of multiple myeloma 102
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 100
CD157 REGULATES THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO CHEMOTHERAPY BY MODULATING THE APOPTOTIC RESPONSE 100
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 99
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 99
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 99
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 98
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 98
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells 96
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 96
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 94
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 94
A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility 92
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 92
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 92
[Idiotypic study of human myeloma] 91
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 91
Cytobiological studies in multiple myeloma. 90
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. 90
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 90
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 90
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 90
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 90
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 90
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 89
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 88
Anticancer innovative therapy: Highlights from the ninth annual meeting 88
Difference in polyamine transport in human B and T lymphocytes. 87
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 87
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. 87
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. 86
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 86
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter. 85
Cyclosporin A and dipyridamole: an effective combination against the generation of cytotoxic T lymphocytes (CTL). 84
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 84
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 84
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 84
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 83
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 83
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 82
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS 82
Autografting followed by low dose TBI based non myeloablative allografting in newly diagnosed multiple myeloma: The Italian experience. 82
Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. 81
Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. 81
Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-0-tetradecanoilphorbol-13-acetate (TPA). 81
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells 81
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 81
B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. 81
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: Diagnostic challenges and therapeutic options: Two case reports 81
Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. 80
5'nucleotidase, adenosine deaminase and purine nucleoside phosphorylase activities in acute leukaemia. 80
null 80
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 80
[Prognostic factors in multiple myeloma] 79
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS 79
Totale 12.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.110
article - articoli 0
book - libri 0
conference - conferenze 23.134
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.405 0 0 147 250 202 461 360 152 221 252 207 153
2020/20212.693 271 155 170 156 291 125 175 134 321 209 377 309
2021/20223.011 108 89 91 218 123 57 463 159 104 326 648 625
2022/20233.960 415 321 93 347 353 997 312 255 415 132 204 116
2023/20241.918 225 363 120 101 110 344 53 104 15 104 132 247
2024/2025331 37 294 0 0 0 0 0 0 0 0 0 0
Totale 21.237